Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
The m6A methyltransferase METTL16 negatively regulates MCP1 expression in mesenchymal stem cells during monocyte recruitment
Zhaoqiang Zhang, Zhongyu Xie, Jiajie Lin, Zehang Sun, Zhikun Li, Wenhui Yu, Yipeng Zeng, Guiwen Ye, Jinteng Li, Feng Ye, Zepeng Su, Yunshu Che, Peitao Xu, Chenying Zeng, Peng Wang, Yanfeng Wu, Huiyong Shen
Zhaoqiang Zhang, Zhongyu Xie, Jiajie Lin, Zehang Sun, Zhikun Li, Wenhui Yu, Yipeng Zeng, Guiwen Ye, Jinteng Li, Feng Ye, Zepeng Su, Yunshu Che, Peitao Xu, Chenying Zeng, Peng Wang, Yanfeng Wu, Huiyong Shen
View: Text | PDF
Research Article Immunology Stem cells

The m6A methyltransferase METTL16 negatively regulates MCP1 expression in mesenchymal stem cells during monocyte recruitment

  • Text
  • PDF
Abstract

Mesenchymal stem cells (MSCs) possess strong immunoregulatory functions, one aspect of which is recruiting monocytes from peripheral vessels to local tissue by secreting monocyte chemoattractant protein 1 (MCP1). However, the regulatory mechanisms of MCP1 secretion in MSCs are still unclear. Recently, the N6-methyladenosine (m6A) modification was reported to be involved in the functional regulation of MSCs. In this study, we demonstrated that methyltransferase-like 16 (METTL16) negatively regulated MCP1 expression in MSCs through the m6A modification. Specifically, the expression of METTL16 in MSCs decreased gradually and was negatively correlated with the expression of MCP1 after coculture with monocytes. Knocking down METTL16 markedly enhanced MCP1 expression and the ability to recruit monocytes. Mechanistically, knocking down METTL16 decreased MCP1 mRNA degradation, which was mediated by the m6A reader YTH N6-methyladenosine RNA-binding protein 2 (YTHDF2). We further revealed that YTHDF2 specifically recognized m6A sites on MCP1 mRNA in the CDS region and thus negatively regulated MCP1 expression. Moreover, an in vivo assay showed that MSCs transfected with METTL16 siRNA showed greater ability to recruit monocytes. These findings reveal a potential mechanism by which the m6A methylase METTL16 regulates MCP1 expression through YTHDF2-mediated mRNA degradation and suggest a potential strategy to manipulate MCP1 expression in MSCs.

Authors

Zhaoqiang Zhang, Zhongyu Xie, Jiajie Lin, Zehang Sun, Zhikun Li, Wenhui Yu, Yipeng Zeng, Guiwen Ye, Jinteng Li, Feng Ye, Zepeng Su, Yunshu Che, Peitao Xu, Chenying Zeng, Peng Wang, Yanfeng Wu, Huiyong Shen

×

Figure 3

METTL16 regulates MCP1 m6A modification and its mRNA stability.

Options: View larger image (or click on image) Download as PowerPoint
METTL16 regulates MCP1 m6A modification and its mRNA stability.
(A and B...
(A and B) m6A modification levels of MCP1 mRNA in siNC-/siMETTL16- or OE NC–/OE METTL16–treated MSCs (n = 3). (C) MCP1 promoter activity in siNC- or siMETTL16-treated MSCs (n = 9) expressed as the ratio of firefly versus Renilla luciferase (Fluc/Rluc). (D) Relative expression of MCP1 precursor mRNA (pre-MCP1) and mature mRNA (MCP1) in siNC- or siMETTL16-treated MSCs (n = 9). (E) Degradation curves of MCP1 mRNA in OE NC– or OE METTL16–treated MSCs (n = 9). (F) Degradation curves of MCP1 mRNA in siNC- or siMETTL16-treated MSCs (n = 9). (G) The t1/2 analysis of MCP1 mRNA in siNC-/siMETTL16- or OE NC–/OE METTL16–treated MSCs (n = 9). (H) The abundance of MCP1 mRNA on polysomes was not changed significantly with knockdown of METTL16 (n = 9). Data are presented as the mean ± SD. Two-tailed Student’s t test was performed in panels A–D and G. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. NS, not significant; MSCs, mesenchymal stem cells. MCP1, monocyte chemoattractant protein 1; siNC, control siRNA; siMETTL16, siRNA for METTL16; OE NC, control lentiviruses; OE METTL16, lentiviruses overexpressing METTL16.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts